宁波华翔：华翔启源与大寰机器人签订战略合作协议在灵巧手的研发等领域加强合作 宁波华翔公告，2025年12月22日，宁波华翔电子股份有限公司子公司宁波华翔启源科技有限公司与深圳 市大寰机器人科技有限公司共同签订了《战略合作协议》，为加快建设通用机器人产业，推动通用机器 人供应链示范和产品创新双驱动，本着依法合规、优势互补、友好协商、互利共赢的原则，双方拟在通 用人形机器人灵巧手的研发、制造和销售等领域加强合作。本协议无需提交公司董事会或者股东大会审 议，公司将根据后续合作业务的进展情况依法依规及时履行相应的决策程序及信息披露义务。 登录新浪财经APP 搜索【信披】查看更多考评等级 12月22日，旭升集团实际控制人变更为广州市人民政府；凌云光拟不超过500万美元认购智谱香港 IPO；华翔启源与大寰机器人签订战略合作协议，在灵巧手的研发等领域加强合作…… 以下是盘后公告精选： 旭升集团：实际控制人变更为广州市人民政府股票复牌 旭升集团公告，公司控股股东、实际控制人徐旭东及其一致行动人正在筹划涉及所持有公司股份转让事 宜，该事项可能导致公司控制权变更。2025年12月22日，徐旭东、陈兴方、旭晟控股、旭日实业与广州 ...

近日，北京万泰生物药业股份有限公司（以下简称"公司"）全资子公司厦门万泰沧海生物技术有限公司 参加了2025年国家免疫规划疫苗集中采购项目一双价人乳头瘤病毒疫苗采购项目的投标工作，公司双价 人乳头瘤病毒疫苗（大肠埃希菌）入围。现将有关情况公告如下： 一、入围产品的基本情况 公司双价人乳头瘤病毒疫苗（大肠埃希菌）入围2025年国家免疫规划疫苗集中采购项目一双价人乳头瘤 病毒疫苗采购项目，入围单价为人民币27.5元。公司双价人乳头瘤病毒疫苗（大肠埃希菌）适用于预防 因高危型人乳头瘤病毒（HPV）16、18型所致下列疾病：宫颈癌，2级、3级宫颈上皮内瘤样病变 （CIN2/3）和原位腺癌（AIS），1级宫颈上皮内瘤样病变（CIN1）以及HPV16型、18型引起的持续感 染。公司积极响应世界卫生组织倡议，助力推动全球消除宫颈癌战略，截至本公告披露日，公司入围产 品全球销量约8,000万剂。本次产品入围将进一步提升我国HPV疫苗接种率，助力我国加速迈向消除宫 颈癌的目标。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603392 证券简称：万泰生物 公告编号：2025-066 北京万泰生物药业股份有限公司 ...

Core Viewpoint - The company, Wantai Biological Pharmacy Enterprise Co., Ltd., has successfully bid for the national immunization program's procurement project for the bivalent human papillomavirus (HPV) vaccine, which is expected to enhance its market presence and contribute to cervical cancer elimination efforts in China [1][2]. Group 1: Vaccine Procurement and Market Impact - The company's bivalent HPV vaccine (E. coli) has been included in the national procurement project with a unit price of 27.5 yuan [1]. - The inclusion of the vaccine is anticipated to increase the vaccination rate in China and support the country's goal of eliminating cervical cancer [1]. - The company acknowledges that the domestic market for bivalent HPV vaccines is under pressure due to the availability of imported nine-valent HPV vaccines and changing consumer preferences [2]. Group 2: Recent Developments and Financial Performance - The company has received acceptance for its clinical trial application for a recombinant respiratory syncytial virus vaccine, marking a significant step in its vaccine development strategy [2]. - For the first three quarters of the year, the company reported revenue of 1.498 billion yuan, a year-on-year decrease of 23.09%, and a net loss of 173 million yuan [3]. - In the third quarter, the company achieved revenue of 655 million yuan, reflecting a year-on-year growth of 12.5%, but still reported a net loss of approximately 29.38 million yuan [3].

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

北京商报讯（记者 丁宁）12月22日晚间，万泰生物（603392）发布公告称，公司全资子公司厦门万泰 沧海生物技术有限公司参加了2025年国家免疫规划疫苗集中采购项目—双价人乳头瘤病毒疫苗采购项目 的投标工作，公司双价人乳头瘤病毒疫苗（大肠埃希菌）入围，入围单价为27.5元。 万泰生物表示，本次集中采购是中国疾病预防控制中心组织的国家免疫规划疫苗集中采购项目，若公司 后续签订采购合同并组织生产与供应，将有利于扩大入围产品的销售规模，提高市场占有率，促进公司 入围产品国内市场的开拓，提升公司的品牌影响力。 ...

本次集中采购是中国疾病预防控制中心组织的国家免疫规划疫苗集中采购项目，若公司后续签订采购合 同并组织生产与供应，将有利于扩大入围产品的销售规模，提高市场占有率，促进公司入围产品国内市 场的开拓，提升公司的品牌影响力。 格隆汇12月22日丨万泰生物(603392.SH)公布,近日，公司全资子公司厦门万泰沧海生物技术有限公司参 加了2025年国家免疫规划疫苗集中采购项目—双价人乳头瘤病毒疫苗采购项目的投标工作，公司双价人 乳头瘤病毒疫苗(大肠埃希菌)入围。 公司双价人乳头瘤病毒疫苗(大肠埃希菌)入围 2025 年国家免疫规划疫苗集中采购项目—双价人乳头瘤 病毒疫苗采购项目，入围单价为人民币27.5元。公司双价人乳头瘤病毒疫苗(大肠埃希菌)适用于预防因 高危型人乳头瘤病毒(HPV)16、18型所致下列疾病：宫颈癌，2级、3级宫颈上皮内瘤样病变(CIN2/3)和 原位腺癌(AIS)，1级宫颈上皮内瘤样病变(CIN1)以及 HPV16型、18型引起的持续感染。公司积极响应世 界卫生组织倡议，助力推动全球消除宫颈癌战略，截至本公告披露日，公司入围产品全球销量约8000万 剂。本次产品入围将进一步提升我国HPV疫苗接种率， ...

Core Viewpoint - Company WanTai BioPharma (603392.SH) has successfully entered the bidding for the 2025 National Immunization Program vaccine procurement project for the bivalent human papillomavirus (HPV) vaccine, with a unit price of RMB 27.5 [1][2] Group 1 - The bivalent HPV vaccine (E. coli) is designed to prevent diseases caused by high-risk HPV types 16 and 18, including cervical cancer and various grades of cervical intraepithelial neoplasia (CIN) [1] - The company has responded to the World Health Organization's initiative to eliminate cervical cancer globally, with approximately 80 million doses of the product sold worldwide as of the announcement date [1] - The inclusion of the product in the procurement project is expected to enhance HPV vaccination rates in China, contributing to the country's goal of eliminating cervical cancer [1] Group 2 - The centralized procurement is organized by the Chinese Center for Disease Control and Prevention, and if the company signs procurement contracts and organizes production and supply, it will help expand the sales scale of the included product [2] - This development is anticipated to increase the market share of the company's included products and enhance its brand influence in the domestic market [2]

北京万泰生物药业股份有限公司 关于全资子公司参与国家免疫规划疫苗集中采购 项目入围的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京万泰生物药业股份有限公司（以下简称"公司"）全资子公司厦门 万泰沧海生物技术有限公司参加了 2025 年国家免疫规划疫苗集中采购项目—双价 人乳头瘤病毒疫苗采购项目的投标工作，公司双价人乳头瘤病毒疫苗（大肠埃希菌） 入围。现将有关情况公告如下： 一、入围产品的基本情况 公司双价人乳头瘤病毒疫苗（大肠埃希菌）入围 2025 年国家免疫规划疫苗集中 采购项目—双价人乳头瘤病毒疫苗采购项目，入围单价为人民币 27.5 元。公司双价 人乳头瘤病毒疫苗（大肠埃希菌）适用于预防因高危型人乳头瘤病毒（HPV）16、 18 型所致下列疾病：宫颈癌，2 级、3 级宫颈上皮内瘤样病变（CIN2/3）和原位腺 癌（AIS），1 级宫颈上皮内瘤样病变（CIN1）以及 HPV16 型、18 型引起的持续 感染。公司积极响应世界卫生组织倡议，助力推动全球消除宫颈癌战略，截至本 公告披露日，公司入围产品全球销量 ...

Core Viewpoint - Company’s subsidiary has successfully participated in a national vaccine procurement project, which could enhance its market presence and brand influence [1] Group 1: Company Developments - WanTai Biological's subsidiary, Xiamen WanTai Canghai Biotechnology Co., Ltd., has entered the bidding for the national immunization program's dual-valent human papillomavirus vaccine procurement project [1] - The dual-valent human papillomavirus vaccine (E. coli) has been shortlisted for the procurement [1] Group 2: Market Implications - If the company signs a procurement contract and organizes production and supply, it will help expand the sales scale of the shortlisted products [1] - This development is expected to improve the company's market share and facilitate the domestic market expansion of its shortlisted products [1] - The initiative will also enhance the company's brand influence in the market [1]

本次集中采购是中国疾病预防控制中心组织的国家免疫规划疫苗集中采购项目，若公司后续签订采购合 同并组织生产与供应，将有利于扩大入围产品的销售规模，提高市场占有率，促进公司入围产品国内市 场的开拓，提升公司的品牌影响力。 智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司厦门万泰沧海生物技术有限 公司参加了2025年国家免疫规划疫苗集中采购项目—双价人乳头瘤病毒疫苗采购项目的投标工作，公司 双价人乳头瘤病毒疫苗(大肠埃希菌)入围。 ...